Genomic Health (GHDX +1.5%) moves up after beating Q4 estimates yesterday. Total revenue increased by 13% Y/Y, driven by a 10% rise in Oncotype DX(R) test results. For the year, the company expects FY13 EPS of $0.48 - $0.68, versus consensus of $0.28. It projects revenues to be $258 mln - $266 mln. The Street view is $263.90 mln in revenues.